The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Méndez-Echevarría A, Fernandez-Prieto A, de la Serna O, Lopez-Gutierrez JC, Parron M, Marin-Aguilera B, Calvo C

Acute Lung Toxicity After Intralesional Bleomycin Sclerotherapy.

Pediatrics. 2018;141(1)

Madabhavi I, Modi G, Patel A, Anand A, Panchal H, Parikh S

Pulmonary toxicity following bleomycin use: A single-center experience.

Journal of cancer research and therapeutics. 2017;13(3):466-470

Ahmed BM, Al-Zakwani IS

Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2013;19(1):3-7

Ngeow J, Tan IB, Kanesvaran R, Tan HC, Tao M, Quek R, Lim ST

Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.

Annals of hematology. 2011;90(1):67-72

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(30):7614-20

Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP

Pulmonary complications associated with combination chemotherapy programs containing bleomycin.

The American journal of medicine. 1983;74(4):557-63

Balikian JP, Jochelson MS, Bauer KA, Skarkin AT, Garnick MB, Canellos GP, Smith EH

Pulmonary complications of chemotherapy regimens containing bleomycin.

AJR. American journal of roentgenology. 1982;139(3):455-61

McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR

Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency.

Cancer. 1987;60(11):2617-20

Dineen MK, Englander LS, Huben RP

Bleomycin-induced nodular pulmonary fibrosis masquerading as metastatic testicular cancer.

The Journal of urology. 1986;136(2):473-5